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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) 
and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic 
abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD 
and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance.
Methods: The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. 
Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum 
liver enzyme concentrations, and daily alcohol consumption were assessed.
Results: Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The 
prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more 
prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and 
AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to 
subjects with normal LFTs (53% and 14%, p < 0.0001 for both).
Discussion and conclusion: In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of 
AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD 
compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with 
NAFLD.
Background
Non-alcoholic fatty liver disease (NAFLD) is defined as a
fatty liver (liver fat >5-10% of liver weight), which is not
due to excess alcohol consumption or other causes of ste-
atosis [1]. NAFLD is associated with obesity, the meta-
bolic syndrome, dyslipidemia, insulin resistance, and type
2 diabetes [1]. NAFLD is the most common cause of ele-
vated liver function tests (LFTs) in the US according to
the NHANES III survey [2]. Population-based studies
from the US have reported the prevalence of increased
liver fat content to be 34% when measured using quanti-
tative proton magnetic resonance spectroscopy [3] and
~20% when estimated using elevated LFTs [4,5]. How-
ever, excess alcohol consumption is common and could
coexist with NAFLD. Merely focusing on NAFLD by
excluding subjects using excessive amounts of alcohol
may thus underestimate the prevalence of the MetS and
type 2 diabetes in subjects with elevated LFTs. This
would seem particularly important as the long-term
prognosis both with respect to the development of cir-
rhosis and total mortality is much worse for patients with
AFLD than with NAFLD [6,7]. There are, however, no
population-based epidemiological studies investigating
the prevalences of both non-alcoholic and alcoholic fatty
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Page 2 of 7liver diseases (AFLD), and the metabolic abnormalities
associated with these conditions [6].
In the clinic, it is difficult to distinguish between sub-
jects with NAFLD and AFLD using abnormal liver func-
tion tests (LFTs). Increased serum γGT concentration is a
marker of excessive alcohol consumption [8], but serum
γGT concentrations are also increased in NAFLD [9].
There are no population-based data on how serum ALT,
AST and γGT concentrations, or the AST/ALT-ratio may
help in distinguishing between NAFLD and AFLD.
In the present study, we examined the prevalence and
metabolic abnormalities of NAFLD and AFLD in a large
population-based cohort of 2766 individuals in which
features of insulin resistance, glucose tolerance status,
and serum liver enzyme concentrations were measured.
Information on alcohol consumption was assessed using
self-administered questionnaire.
Methods
Subjects
The FIN-D2D survey was carried out in the hospital dis-
tricts of Pirkanmaa, the Southern Ostrobothnia, and
Central Finland between October and December 2007. A
random sample of 4500 subjects aged 45-74 years, strati-
fied according to gender, 10-year age groups (45-54, 55-
64, and 65-74 years), and the three geographical areas,
was selected from the National Population Register in
August 2007. The study participants were invited to a
clinical examination by mail. The overall participation
rate was 64%. Subjects for which fasting blood samples or
reliable 2-hour post-challenge glucose results in the
OGTT were unavailable were excluded from the analyses
(n = 39). In addition, subjects without data on alcohol
consumption were excluded (n = 63). The total number of
individuals included was thus 2766 (61% of the original
sample).
The study protocol was approved by the Ethical Com-
mittee of the Hospital District of Helsinki and Uusimaa.
All participants gave their written informed consent prior
to participation in the study.
Design
The health examination was carried out according to the
WHO MONICA project [10] and the WHO Expert
Group for glucose assessments. After an overnight fast,
blood samples were drawn for measurement of fasting
plasma (fP) glucose, fasting serum (fS) insulin, fS-triglyc-
erides, fS-HDL and LDL cholesterol, fS-ALT, fS-AST, and
fS-γGT concentrations. Height, weight, waist circumfer-
ence, and body fat % were measured by nurses specially
trained for the survey procedures. Body composition was
measured using the Tanita TBF-300MA body composi-
tion analyzer (Tanita Corporation Tokyo Japan) based on
the principle of single frequency leg-to-leg bioelectrical
impedance.
An oral glucose tolerance test (OGTT) was performed
in all subjects except for those with previously diagnosed
diabetes (either type 1 or type 2). Alcohol consumption
during the past week and the past year was assessed with
a self-administered questionnaire. The average daily alco-
hol consumption (g/d) was calculated from the number
of drinks during the past week. The results remained
essentially unchanged if the average alcohol consumption
was calculated from the number of drinks during the past
year. The participants were asked whether they were
using lipid lowering, antihypertensive, or antihyperglyce-
mic medications. According to the Finnish Red Cross, the
prevalences of hepatitis B and C were 0.03% and 0.05%
among blood donors (n = 208305) during 1998-2007
including these regions of Finland (Tom Krusius, the
Finnish Red Cross).
Definitions
The cutoffs of fS-ALT or fS-AST concentrations were
determined using data of 271 non-diabetic Finnish sub-
jects [11], in which liver fat content has been directly
measured using proton magnetic resonance spectros-
copy. The regression coefficients and their 95% confi-
dence intervals of relationships between liver fat % and S-
ALT were 0.43 (0.29-0.55) and 0.46 (0.29-0.60) in women
and men, respectively. The regression coefficients and
their 95% confidence intervals of relationships between
liver fat % and S-AST were 0.25 (0.09-0.39) and 0.31
(0.12-0.48) in women and men, respectively. Increased
liver fat content was defined as liver fat >5.6% (based on
the Dallas Heart Study [3]) and corresponded to AST
concentrations of 33 U/l and 29 U/l in men and women,
and to ALT concentrations of 43 U/l and 30 U/l, respec-
tively. Men and women with increased fS-ALT or/and fS-
AST concentrations consuming ≤ 20 g (for men) and ≤ 10
g (for women) of ethanol per day were considered to have
NAFLD [1], while those consuming >20 g (for men) and
>10 g (for women) of ethanol per day were considered to
have AFLD. Additionally, the analyses were validated
using higher cut-off values (30 g and 20 g of ethanol per
day in men and women, respectively) for use of alcohol.
Glucose tolerance was classified according to the WHO
1999 criteria [12]. The OGTT was performed according
to the WHO recommendations [12]. Fasting and 2-hour
samples for measurement of plasma glucose concentra-
tions were drawn into fluoride citrate tubes and centri-
fuged within 30 minutes.
The metabolic syndrome was defined according to cri-
teria of the International Diabetes Federation [13]: central
obesity (waist circumference ≥94 cm in men and ≥80 cm
in women) and at least two of the following factors: 1)
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for this lipid abnormality; 2) serum HDL cholesterol
<1.03 mmol/l in men and <1.29 mmol/l in women or spe-
cific treatment for this lipid abnormality; 3) systolic BP
≥130 mmHg or diastolic BP ≥85 mmHg or treatment for
previously diagnosed hypertension; 4) fasting plasma glu-
cose ≥5.6 mmol/l or previously diagnosed type 2 diabetes.
Analytical procedures and other measurements
All assays were performed at the Laboratory of Analytical
Biochemistry at the National Public Health Institute, Hel-
sinki, using Architect ci8200 analyzer (Abbott Laborato-
ries, Abbott Park, IL). Plasma glucose was determined
with a hexokinase method (Abbott Laboratories, Abbott
Park, IL) and serum insulin with a chemiluminescent
microparticle immunoassay (Abbott Laboratories,
Abbott Park, IL). Serum total and HDL cholesterol, and
triglyceride concentrations were measured with enzy-
matic kits from Abbott Laboratories (Abbott Park, IL).
The concentrations of LDL cholesterol were calculated
using the Friedewald formula [14]. Serum ALT, AST, and
γGT concentrations were determined using photometric
IFCC (International Federation of Clinical Chemistry)
methods (Abbott Laboratories, Abbott Park, IL).
Height was measured to the nearest 0.1 cm. Weight was
measured in light clothing. BMI was calculated as weight
(kg) divided by height2 (m2). Blood pressure was mea-
sured in a sitting position after a minimum of 15 minutes
of acclimatization and before blood sampling using a
mercury sphygmomanometer.
Statistical analyses
Characteristics of the study population are given as
means and standard deviations (SD). The differences in
clinical and laboratory data between the groups in Addi-
tional file 1 were compared using analysis of covariance
for continuous variables, and logistic regression analysis
for dichotomous variables. Prevalences of elevated LFTs
were compared with logistic regression models, using
likelihood-ratio tests. These analyses were additionally
adjusted for age, gender, and BMI. Analyses were per-
formed with the statistics package Stata version 9.2 [15].
Results
Prevalence of elevated liver function tests (LFTs)
Elevated LFTs were present in 28% (95% CI: 26%-29%) of
the subjects. The prevalences of NAFLD and AFLD were
21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%) (Figure
1). Characteristics of subjects with and without elevated
LFTs and either low or high alcohol consumption are
shown in Additional file 1. Clinical and biochemical char-
acteristics of subjects with normal LFTs were essentially
similar in those with low or high alcohol consumption.
Subjects with NAFLD had similar BMI, waist, whole body
fat %, fP-glucose, 2h-glucose, and fS-insulin concentra-
tions as subjects with AFLD (Additional file 1). The AST/
ALT-ratio was similar, fS-ALT 9%, fS-AST 12%, and S-
γGT concentrations 43% higher in AFLD as compared to
NAFLD (Additional file 1, Figure 2).
NAFLD and AFLD in the metabolic syndrome, IGT, and type 
2 diabetes
In subjects with NAFLD and AFLD, the prevalences of
the metabolic syndrome were 70% and 73% (p = 0.028,
NAFLD vs. AFLD, Figure 3a). These prevalences were
significantly higher than in subjects with normal LFTs
(53% in subjects with low and high alcohol consumption,
p = 0.001 for both, p = 0.01 after adjusting for age, gender,
and BMI). The prevalence of IGT was 20% in NAFLD and
16% in AFLD (NS, NAFLD vs. AFLD, Figure 3b), which
was not different from subjects with normal LFTs (18%).
Type 2 diabetes was present in 25% of subjects with
NAFLD and 24% of subjects with AFLD (NS, NAFLD vs.
AFLD, Figure 3c). These prevalences were significantly
higher compared to subjects with normal LFTs (14%, p <
0.001 for both, p < 0.0001 after adjusting for age, gender,
and BMI).
The metabolic syndrome, IGT, and type 2 diabetes in 
NAFLD and AFLD
In subjects with the metabolic syndrome, the prevalences
of NAFLD and AFLD were significantly higher as com-
pared to those without the syndrome (p = 0.001 for both,
p = 0.02 after adjusting for age, gender, and BMI, Figure
4). The prevalences of NAFLD and AFLD were similar in
subjects with and without IGT. In subjects with type 2
diabetes, the prevalences of NAFLD and AFLD were sig-
nificantly higher as compared to subjects without type 2
diabetes (p = 0.01 for both, p = 0.01 after adjusting for
age, gender, and BMI).
When the above-described analyses were replicated by
defining NAFLD and ALFD using higher cut-off values
for alcohol use (30 g and 20 g of ethanol per day in men
and women, respectively), the main results comparing
Figure 1 The prevalence of elevated LFTs due to non-alcoholic 
(NAFLD) and alcoholic (AFLD) causes in 2766 Finnish subjects.
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LFTs
28%
NAFLD
75%
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Normal
LFTs
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essentially unchanged.
Discussion
To our knowledge, this is the first population-based study
comparing prevalences and associated metabolic abnor-
malities between NAFLD and AFLD. In the present study,
the prevalence of NAFLD was 21% when estimated using
elevated LFTs, in keeping with recent population-based
surveys in which the prevalence of NAFLD was estimated
using abnormal LFTs [5]. The metabolic syndrome and
type 2 diabetes in AFLD were as prevalent as in NAFLD.
In NAFLD, LFTs are only mildly or moderately ele-
vated. We therefore did not use cut-offs of elevated liver
enzymes from routine laboratory (S-ALT > 70 U/l in men
and > 45 U/l in women, S-AST > 45 U/l in men and > 35
U/l in women) but rather cut-off values which in our lab-
oratory corresponded to increased liver fat content mea-
sured with 1H-MRS (>5.6% [3]). As these cut-off values
are based on estimated associations between liver fat and
liver enzymes in a study sample, there is some inheritent
uncertainty in the diagnostic limits, as illustrated by the
confidence intervals for the estimates of regression coef-
ficients. However, these cut-off values were almost identi-
cal to those suggested by Prati et al [16] for identification
of subjects with liver disease. Both the AST/ALT-ratio [8]
and serum γGT concentrations [8,17] have been sug-
gested to be more specific to alcoholic liver disease than
NAFLD [18-21]. In the present study, subjects with AFLD
consumed 10-times more alcohol than subjects with
NAFLD, but there were no clinically significant differ-
ences in S-ALT, S-AST, or AST/ALT-ratio between the
two groups. S-γGT concentrations were ~2-fold higher in
AFLD compared to NAFLD, confirming that S-γGT is a
useful marker of alcohol-induced liver disease.
Approximately one third of the population worldwide
has the metabolic syndrome [22]. The prevalence
increases with age [22]. In our cohort of 45-74 yrs old
subjects, approximately 70% of subjects with NAFLD had
the metabolic syndrome, which was significantly higher
than in subjects with normal LFTs (53%). Due to a large
sample size, there is a potential to identify very small dif-
Figure 2 (A) S-ALT concentrations, (B) S-AST concentrations, (C) AST/ALT-ratio, and (D) S-γGT concentrations in subjects with normal LFTs 
[subjects with low (n = 1691) or high (n = 308) alcohol consumption, Additional file 1], NAFLD, and AFLD. For differences between normal LFTs 
vs. NAFLD or AFLD, please see Additional file 1. *p < 0.05, *p < 0.01, ***p < 0.001. The error-bars are standard error of the mean.
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may not be of a clinical significance, but differences in
BMI, liver enzymes, triglyceride and fasting glucose con-
centrations between subjects with and without fatty liver
disease should be considered as clinically relevant. In the
present study, the AFLD and NAFLD groups were com-
parable with respect to BMI, waist circumference, % body
fat and glucose and insulin concentrations (Additional
file 1). Despite nearly similar prevalences of the metabolic
syndrome, the AFLD group had significantly higher HDL
cholesterol and higher triglycerides than the NAFLD
group (Additional file 1). In the face of otherwise
matched groups, these lipid differences are likely to be
due to alcohol, which is known to increase both HDL
cholesterol and triglyceride concentrations [23,24]. Dia-
stolic blood pressure was also significantly higher in
AFLD than in NAFLD, which could also be due to alcohol
use independent of obesity and insulin [25].
NAFLD predicts type 2 diabetes independent of obesity
[26]. A small study of 114 subjects with bright liver and
chronically elevated LFTs suggested that approximately
half of subjects with NAFLD have impaired or diabetic
glucose tolerance [27]. We found the prevalence of type 2
diabetes to be 25% in NAFLD and 24% in AFLD, which
was significantly higher than in subjects with normal
LFTs (14%). In previous studies of subjects with biopsy-
proven NAFLD, the prevalence of type 2 diabetes has
ranged from 20 to 50% [5,28]. These data suggest that an
OGTT should be considered in subjects with even mildly
elevated LFTs.
The strengths of the present study include a popula-
tion-based approach and a large and representative sam-
ple of middle-aged individuals studied in three districts of
Finland where the prevalence of hepatitis is low. In addi-
tion, all measurements were performed centrally using
the same methods. However, our study has several limita-
tions. First, self-reported alcohol consumption is fre-
quently subject to underreporting. We therefore used low
limits of alcohol consumption to separate subjects with
NAFLD and AFLD [1]. In addition, the results were
essentially similar if alcohol consumption was calculated
from the number of drinks during the past week or year.
Figure 3 The prevalences of (A) the metabolic syndrome, (B) im-
paired glucose tolerance, and (C) type 2 diabetes in subjects with 
normal LFTs [subjects with low (n = 1691) or high (n = 308) alco-
hol consumption, Additional file 1], NAFLD, and AFLD. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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Figure 4 The prevalences of NAFLD and AFLD in subjects with 
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AST to diagnose NAFLD, it is likely that not all subjects
with NAFLD or AFLD were identified due to poor sensi-
tivity of LFTs. This is an epidemiological study on 2766
subjects and measuring liver fat content with proton
magnetic resonance spectroscopy is a challenge in such a
large study population. Third, the cut-off of ethanol
intake is valid to define NAFLD, but values above the cut-
off do not necessarily indicate AFLD. Whenever drinking
is limited to social drinking and is accompanied to excess
energy intake, it is largely possible that in most patients
with alcohol intake above the safe limits, AFLD and a
metabolic liver disease unrelated to alcohol may coexist.
Forth, the participation rate of subjects who consume
excess alcohol might be low, which might underestimate
the true prevalence of AFLD.
Conclusion
In conclusion, when studied in a population-based sur-
vey, AFLD is less prevalent than NAFLD, but the meta-
bolic syndrome and type 2 diabetes are equally common
in these conditions. Thus, it is important to recognize
and treat the metabolic abnormalities not only in subjects
with low but also in those with high alcohol consumption
and mildly elevated LFTs.
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